William Avery

2.5k total citations · 2 hit papers
16 papers, 1.7k citations indexed

About

William Avery is a scholar working on Oncology, Molecular Biology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, William Avery has authored 16 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 6 papers in Molecular Biology and 3 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in William Avery's work include Cancer Treatment and Pharmacology (3 papers), Pancreatic and Hepatic Oncology Research (3 papers) and Monoclonal and Polyclonal Antibodies Research (3 papers). William Avery is often cited by papers focused on Cancer Treatment and Pharmacology (3 papers), Pancreatic and Hepatic Oncology Research (3 papers) and Monoclonal and Polyclonal Antibodies Research (3 papers). William Avery collaborates with scholars based in United States, United Kingdom and Netherlands. William Avery's co-authors include Alexis A. Borisy, Stanley J. Korsmeyer, Lisa M. Johansen, Margaret Lee, Grant R. Zimmermann, Richard J. Rickles, Adrian Heilbut, Joseph Lehár, Andrew Krueger and Xiaowei Jin and has published in prestigious journals such as Cell, Journal of Clinical Oncology and Blood.

In The Last Decade

William Avery

15 papers receiving 1.7k citations

Hit Papers

Synergistic drug combinations tend to improve therapeutic... 2002 2026 2010 2018 2009 2002 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Synergistic drug combinations tend to improve therapeutically relevant selectivity
    2009 742 citations Joseph Lehár, Andrew Krueger et al. Nature Biotechnology profile →
  2. Bcl2 Regulation by the Melanocyte Master Regulator Mitf Modulates Lineage Survival and Melanoma Cell Viability
    2002 578 citations Gaël McGill, Martin A. Horstmann et al. Cell profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
William Avery United States 8 1.1k 358 291 203 202 16 1.7k
Jens Rauch Ireland 20 1.5k 1.4× 231 0.6× 385 1.3× 290 1.4× 82 0.4× 34 2.2k
Lora Swenson United States 20 2.1k 2.0× 339 0.9× 364 1.3× 130 0.6× 68 0.3× 29 2.9k
Dominic Tisi United Kingdom 15 1.6k 1.5× 347 1.0× 171 0.6× 309 1.5× 42 0.2× 20 2.4k
Mårten Fryknäs Sweden 27 1.7k 1.6× 224 0.6× 799 2.7× 196 1.0× 90 0.4× 77 2.7k
Carol S. Lim United States 21 1.3k 1.2× 110 0.3× 319 1.1× 162 0.8× 145 0.7× 72 2.1k
Dan Lü United States 17 1.1k 1.1× 473 1.3× 277 1.0× 207 1.0× 300 1.5× 36 2.1k
Byung Il Lee South Korea 27 1.1k 1.0× 141 0.4× 194 0.7× 140 0.7× 103 0.5× 86 2.0k
Kyung Bo Kim United States 23 1.8k 1.7× 272 0.8× 769 2.6× 268 1.3× 89 0.4× 61 2.6k
Florian Rothweiler Germany 23 1.1k 1.0× 122 0.3× 562 1.9× 105 0.5× 327 1.6× 56 2.0k
Raghavendra Gowda United States 20 695 0.7× 84 0.2× 248 0.9× 165 0.8× 90 0.4× 37 1.2k

Countries citing papers authored by William Avery

Since Specialization
Citations

This map shows the geographic impact of William Avery's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William Avery with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William Avery more than expected).

Fields of papers citing papers by William Avery

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William Avery. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William Avery. The network helps show where William Avery may publish in the future.

Co-authorship network of co-authors of William Avery

This figure shows the co-authorship network connecting the top 25 collaborators of William Avery. A scholar is included among the top collaborators of William Avery based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William Avery. William Avery is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
2.
O’Neil, Jennifer, Manoussa Fanny, Justin Greene, et al.. (2021). Tumor-selective activity of XTX202, a protein-engineered IL-2, in mice without peripheral toxicities in nonhuman primates.. Journal of Clinical Oncology. 39(15_suppl). 2563–2563. 15 indexed citations
3.
Scranton, Richard E., et al.. (2020). Ultra long‐acting oral therapies for Alzheimer's: Proof of principle. Alzheimer s & Dementia. 16(S9). 2 indexed citations
4.
5.
O’Reilly, Eileen M., Devalingam Mahalingam, James Roach, et al.. (2017). Necuparanib combined with nab-paclitaxel + gemcitabine in patients with metastatic pancreatic cancer: Phase 2 results.. Journal of Clinical Oncology. 35(4_suppl). 370–370. 5 indexed citations
6.
Ling, Lei, S. Roy, James W. Meador, et al.. (2015). THU0057 Targeting the Neonatal FC Receptor (FCRN) to Mediate Autoantibody Clearance in IgG-Driven Autoimmune Disease. Annals of the Rheumatic Diseases. 74. 212–212. 1 indexed citations
7.
Rickles, Richard J., Winnie F. Tam, Thomas P. Giordano, et al.. (2012). Adenosine A2A and Beta-2 Adrenergic Receptor Agonists: Novel Selective and Synergistic Multiple Myeloma Targets Discovered through Systematic Combination Screening. Molecular Cancer Therapeutics. 11(7). 1432–1442. 13 indexed citations
8.
Schultes, Birgit C., Martijn P. Lolkema, Chia Lin Chu, et al.. (2012). M402, a heparan sulfate mimetic and novel candidate for the treatment of pancreatic cancer.. Journal of Clinical Oncology. 30(15_suppl). 4056–4056. 3 indexed citations
9.
Chu, Chia Lin, Alison Long, Jay Duffner, et al.. (2012). Abstract 1524: M402, a novel heparan sulfate mimetic, inhibits pancreatic tumor growth and desmoplasia potentially via sonic hedgehog signaling in an orthotopic mouse model. Cancer Research. 72(8_Supplement). 1524–1524. 1 indexed citations
10.
Lehár, Joseph, Andrew Krueger, William Avery, et al.. (2009). Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nature Biotechnology. 27(7). 659–666. 742 indexed citations breakdown →
11.
Zimmermann, Grant R., et al.. (2009). Selective amplification of glucocorticoid anti-inflammatory activity through synergistic multi-target action of a combination drug. Arthritis Research & Therapy. 11(1). R12–R12. 39 indexed citations
12.
Draganov, Dragomir, et al.. (2009). Pharmacokinetics of M118, unfractionated heparin and enoxaparin sodium in normal and 5/6 nephrectomized uremic rats. Toxicology Letters. 189. S113–S113. 1 indexed citations
13.
Rickles, Richard J., Laura Pierce, Thomas P. Giordano, et al.. (2008). Adenosine A2A and Beta-2 Adrenergic Receptor Agonism: Novel Selective and Synergistic Multiple Myeloma Targets Discovered through Systematic Combination Screening. Blood. 112(11). 384–384. 1 indexed citations
14.
Lee, Margaret, Lisa M. Johansen, Yanzhen Zhang, et al.. (2007). The Novel Combination of Chlorpromazine and Pentamidine Exerts Synergistic Antiproliferative Effects through Dual Mitotic Action. Cancer Research. 67(23). 11359–11367. 90 indexed citations
15.
Ernst, Patricia, et al.. (2004). Definitive Hematopoiesis Requires the Mixed-Lineage Leukemia Gene. Developmental Cell. 6(3). 437–443. 199 indexed citations
16.
McGill, Gaël, Martin A. Horstmann, Hans R. Widlund, et al.. (2002). Bcl2 Regulation by the Melanocyte Master Regulator Mitf Modulates Lineage Survival and Melanoma Cell Viability. Cell. 109(6). 707–718. 578 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jens Rauch Breakdown of academic impact, for papers by Lora Swenson Breakdown of academic impact, for papers by Dominic Tisi Breakdown of academic impact, for papers by Mårten Fryknäs Breakdown of academic impact, for papers by Carol S. Lim Breakdown of academic impact, for papers by Dan Lü Breakdown of academic impact, for papers by Byung Il Lee Breakdown of academic impact, for papers by Kyung Bo Kim Breakdown of academic impact, for papers by Florian Rothweiler Breakdown of academic impact, for papers by Raghavendra Gowda
Rankless by CCL
2026